Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes

Health Services Research

Volumn 45, Issue 2, 2010, Pages 437-456

  Timbie, Justin W ^c   Hayward, Rodney A ^a,b   Vijan, Sandeep ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE

Author keywords

Diabetes mellitus; Monte Carlo simulation; Outcomes research; Quality measurement

Indexed keywords

ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE PLUS SIMVASTATIN; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SIMVASTATIN; SULFONYLUREA; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CLINICAL EVALUATION; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC PATIENT; DRUG DOSE REGIMEN; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OUTCOME ASSESSMENT; POLYPHARMACY; RISK FACTOR; THERAPY EFFECT; TREATMENT RESPONSE;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MONTE CARLO METHOD; NUTRITION SURVEYS; OUTCOME ASSESSMENT (HEALTH CARE); POLYPHARMACY; QUALITY OF HEALTH CARE;

EID: 77949305134     PISSN: 00179124     EISSN: 14756773     Source Type: Journal    
DOI: 10.1111/j.1475-6773.2009.01075.x     Document Type: Article

References (35)

1. Abraira, C., J. A. Colwell, F. Q. Nuttall, C. T. Sawin, N. J. Nagel, J. P. Comstock, N. V. Emanuele, S. R. Levin, W. Henderson H. S. Lee. 1995 Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). Results of the Feasibility Trial. Veterans Affairs Cooperative Study in Type II Diabetes Diabetes Care 18 (8) : 1113 1123.
2. American Diabetes Association. 2008 Standards of Medical Care in Diabetes-2008 Diabetes Care 31 (suppl 1) : S12 54.
3. Fleming, T. R. D. L. DeMets. 1996 Surrogate End Points in Clinical Trials: Are We Being Misled? Annals of Internal Medicine 125 (7) : 605 613.
4. Food and Drug Administration. 2000 From the Food and Drug Administration Journal of the American Medical Association 283 (17) : 2228.
5. Grundy, S. M., J. I. Cleeman, C. N. Merz, H. B. Jr. Brewer, L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Jr. Smith N. J. Stone. 2004 Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation 110 (2) : 227 239.
6. Hansson, L., A. Zanchetti, S. G. Carruthers, B. Dahlof, D. Elmfeldt, S. Julius, J. Menard, K. H. Rahn, H. Wedel S. Westerling. 1998 Effects of Intensive Blood-Pressure Lowering and Low-Dose Aspirin in Patients with Hypertension: Principal Results of the Hypertension Optimal Treatment (HOT) Randomised Trial. HOT Study Group Lancet 351 (9118) : 1755 1762.
7. Hayward, R. A., T. P. Hofer S. Vijan. 2006 Narrative Review: Lack of Evidence for Recommended Low-Density Lipoprotein Treatment Targets: A Solvable Problem Annals of Internal Medicine 145 (7) : 520 530.
8. Jones, G. C., J. P. Macklin W. D. Alexander. 2003 Contraindications to the use of Metformin British Medical Journal 326 (7379) : 4 5.
9. Kaplan, S. H., J. L. Griffith, L. L. Price, L. G. Pawlson S. Greenfield. 2009 Improving the Reliability of Physician Performance Assessment: Identifying the "Physician Effect" on Quality and Creating Composite Measures Medical Care 47 (4) : 378 387.
10. Kastelein, J. J., F. Akdim, E. S. Stroes, A. H. Zwinderman, M. L. Bots, A. F. Stalenhoef, F. L. Visseren, E. J. Sijbrands, M. D. Trip, E. A. Stein, D. Gaudet, R. Duivenvoorden, E. P. Veltri, A. D. Marais E. de Groot. 2008 Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia New England Journal of Medicine 358 (14) : 1431 1443.
11. Kerr, E. A., S. L. Krein, S. Vijan, T. P. Hofer R. A. Hayward. 2001 Avoiding Pitfalls in Chronic Disease Quality Measurement: A Case for the Next Generation of Technical Quality Measures American Journal of Managed Care 7 (11) : 1033 1043.
12. Kerr, E. A., D. M. Smith, M. M. Hogan, T. P. Hofer, S. L. Krein, M. Bermann R. A. Hayward. 2003 Building a Better Quality Measure: Are Some Patients with 'Poor Quality' Actually Getting Good Care? Medical Care 41 (10) : 1173 1182.
13. Krumholz, H. M. T. H. Lee. 2008 Redefining Quality-Implications of Recent Clinical Trials New England Journal of Medicine 358 (24) : 2537 2539.
14. Lasser, K. E., P. D. Allen, S. J. Woolhandler, D. U. Himmelstein, S. M. Wolfe D. H. Bor. 2002 Timing of New Black Box Warnings and Withdrawals for Prescription Medications Journal of the American Medical Association 287 (17) : 2215 2220.
15. Law, M. R., N. J. Wald, J. K. Morris R. E. Jordan. 2003a Value of Low Dose Combination Treatment with Blood Pressure Lowering Drugs: Analysis of 354 Randomised Trials British Medical Journal 326 (7404) : 1427 1431.
16. Law, M. R., N. J. Wald A. R. Rudnicka. 2003b Quantifying Effect of Statins on Low Density Lipoprotein Cholesterol, Ischaemic Heart Disease, and Stroke: Systematic Review and Meta-Analysis British Medical Journal 326 (7404) : 1423 1427.
17. Lumley, T. 2008. Analysis of Complex Survey Samples (release 3.10), Available at.
18. Materson, B. J., D. J. Reda, W. C. Cushman, B. M. Massie, E. D. Freis, M. S. Kochar, R. J. Hamburger, C. Fye, R. Lakshman, J. Gottdiener, E. A. Ramirez, W. E. Henderson, for the Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. 1993 Single-Drug Therapy for Hypertension in Men. A Comparison of Six Antihypertensive Agents with Placebo New England Journal of Medicine 328 (13) : 914 921.
19. McAlister, F. A., N. R. Campbell, M. Duong-Hua, Z. Chen K. Tu. 2006 Antihypertensive Medication Prescribing in 27,822 Elderly Canadians with Diabetes over the Past Decade Diabetes Care 29 (4) : 836 841.
20. Nallamothu, B. K., R. A. Hayward E. R. Bates. 2008 Beyond the Randomized Clinical Trial: The Role of Effectiveness Studies in Evaluating Cardiovascular Therapies Circulation 118 (12) : 1294 1303.
21. Nissen, S. E. K. Wolski. 2007 Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes New England Journal of Medicine 356 (24) : 2457 2471.
22. Patel, A., S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, L. Liu, G. Mancia, C. E. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, S. Bompoint, B. E. de Galan, R. Joshi F. Travert. 2008 Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes New England Journal of Medicine 358 (24) : 2560 2572.
23. Pedersen, T. R., O. Faergeman, J. J. Kastelein, A. G. Olsson, M. J. Tikkanen, I. Holme, M. L. Larsen, F. S. Bendiksen, C. Lindahl, M. Szarek J. Tsai. 2005 High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention after Myocardial Infarction: The Ideal Study: A Randomized Controlled Trial Journal of the American Medical Association 294 (19) : 2437 2445.
24. Psaty, B. M., T. A. Manolio, N. L. Smith, S. R. Heckbert, J. S. Gottdiener, G. L. Burke, J. Weissfeld, P. Enright, T. Lumley, N. Powe C. D. Furberg. 2002 Time Trends in High Blood Pressure Control and the Use of Antihypertensive Medications in Older Adults: The Cardiovascular Health Study Archives of Internal Medicine 162 (20) : 2325 2332.
25. Ross, S. D., K. S. Akhras, S. Zhang, M. Rozinsky L. Nalysnyk. 2001 Discontinuation of Antihypertensive Drugs Due to Adverse Events: A Systematic Review and Meta-Analysis Pharmacotherapy 21 (8) : 940 953.
26. Rubins, H. B., S. J. Robins, D. Collins, C. L. Fye, J. W. Anderson, M. B. Elam, F. H. Faas, E. Linares, E. J. Schaefer, G. Schectman, T. J. Wilt J. Wittes. 1999 Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group New England Journal of Medicine 341 (6) : 410 418.
27. Saha, S. A., L. G. Kizhakepunnur, A. Bahekar R. R. Arora. 2007 The Role of Fibrates in the Prevention of Cardiovascular Disease - a Pooled Meta-Analysis of Long-Term Randomized Placebo-Controlled Clinical Trials American Heart Journal 154 (5) : 943 953.
28. Thompson, W., H. Wang, M. Xie, J. Kolassa, M. Rajan, C. L. Tseng, S. Crystal, Q. Zhang, Y. Vardi, L. Pogach M. M. Safford. 2005 Assessing Quality of Diabetes Care by Measuring Longitudinal Changes in Hemoglobin A1c in the Veterans Health Administration Health Services Research 40 (6, Part 1) : 1818 1835.
29. UKPDS Study Group. 1995 United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative Efficacy of Randomly Allocated Diet, Sulphonylurea, Insulin, or Metformin in Patients with Newly Diagnosed Non-Insulin Dependent Diabetes Followed for Three Years British Medical Journal 310 (6972) : 83 8.
30. UKPDS Study Group. 1998a Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 352 (9131) : 837 853.
31. UKPDS Study Group. 1998b Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. UK Prospective Diabetes Study Group British Medical Journal 317 (7160) : 703 713.
32. Van Buuren, S. C. G. M. Oudshoorn. 2007. Multivariate Imputation by Chained Equations (release 1.16).
33. Werner, R. M., D. A. Asch D. Polsky. 2005 Racial Profiling: The Unintended Consequences of Coronary Artery Bypass Graft Report Cards Circulation 15 (10) : 1257 1263.
34. Wu, J., A. T. Kraja, A. Oberman, C. E. Lewis, R. C. Ellison, D. K. Arnett, G. Heiss, J. M. Lalouel, S. T. Turner, S. C. Hunt, M. A. Province D. C. Rao. 2005 A Summary of the Effects of Antihypertensive Medications on Measured Blood Pressure American Journal of Hypertension 18 (7) : 935 942.
35. Zhang, Q., M. Safford, J. Ottenweller, G. Hawley, D. Repke, J. F. Jr. Burgess, S. Dhar, H. Cheng, H. Naito L. M. Pogach. 2000 Performance Status of Health Care Facilities Changes with Risk Adjustment of HbA1c Diabetes Care 23 (7) : 919 927.